ErbB2 is a prognostic factor and target of therapy for many carcinomas. In contrast with the
other ErbB receptors, ErbB2 lacks a soluble direct ligand, but it is the preferred co-receptor …

Preventing ligand-dependent ErbB2 receptor heterodimers by an anti-ErbB2 monoclonal
antibody shuts down receptor signaling and has potent antitumor activity even in tumors that …

A new human, compact antibody was engineered by fusion of a human, antitumour ErbB2-
directed scFv with a human IgG1 Fc domain. Overexpression of the ErbB2 receptor is related …

Antibodies targeting the extracellular domains of ErbB receptors have been extensively
studied for cancer drug development. This work has led to clinical approval of monoclonal …

ErbB-2 is an orphan receptor that belongs to a family of tyrosine kinase receptors for either
epidermal growth factor (EGF) or Neu differentiation factor (NDF/neuregulin). Because …

erbB2 oncogene encodes a growth factor receptor. The overexpression of erbB2 was
correlated with more aggressive tumors and a poorer prognosis. Some antibodies directed …

Overexpression of the ErbB2 receptor is associated with the progression of breast cancer,
and is a sign of a poor prognosis. Herceptin, a humanized antibody directed to the ErbB2 …

Erbicin is a human anti-ErbB2 single-chain antibody fragment with high affinity and
selectivity for ErbB2-positive cancer cells. Two anti-ErbB2 immunoconjugates, called Erb …

We previously demonstrated that delivery of a gene encoding an anti-erbB-2 intracellular
single-chain antibody (sFv) resulted in down-regulation of cell surface erbB-2 levels and …

Overexpression of the tyrosine kinase receptor erbB2 is important in the pathogenesis of a
variety of neoplasms. Based on this concept, targeted anti-cancer strategies have been …